

Please use this form if you want the Hong Kong Offer Shares to be issued in the name of HKSCC Nominees Limited (“HKSCC Nominees”) and deposited directly into the Central Clearing and Settlement System (“CCASS”) for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant 如閣下欲以香港中央結算(代理人)有限公司(「香港結算代理人」)的名義登記將獲發行的香港發售股份，並直接存入中央結算及交收系統(「中央結算系統」)，以寄存於閣下的中央結算系統投資者戶口持有人股份戶口或閣下指定的中央結算系統參與者股份戶口，請使用本表格

Staple your  
payment here  
請將股款  
緊釘在此

This Application Form uses the same terms as defined in the prospectus of Ascentage Pharma Group International (the “Company”) dated October 16, 2019 (the “Prospectus”).

本申請表格使用亞盛醫藥集團(「本公司」)於二零一九年十月十六日刊發的招股章程(「招股章程」)所界定的相同詞彙。

Neither this Application Form nor the Prospectus constitutes an offer to sell or the solicitation of an offer to buy any Hong Kong Offer Shares in any jurisdiction other than Hong Kong. The Hong Kong Offer Shares may not be offered or sold in the United States without registration or an exemption from registration under the U.S. Securities Act.

本申請表格及招股章程概不構成在香港以外的任何司法轄區要約出售或游說要約購買任何香港發售股份。若無根據美國證券法登記或獲豁免登記，香港發售股份不得在美國提呈發售或出售。

This Application Form and the Prospectus may not be forwarded or distributed or reproduced (in whole or in part) in any jurisdiction whatsoever in any jurisdiction where such forwarding, distribution or reproduction is not permitted under the law of that jurisdiction. Any such forwarding, distribution or reproduction in any jurisdiction where such forwarding, distribution or reproduction is not permitted under the law of that jurisdiction (notwithstanding whether such forwarding, distribution or reproduction is made by electronic means) is prohibited. Any person who forwards, distributes or reproduces this Application Form or the Prospectus in any such jurisdiction may be liable to legal action. Copies of this Application Form and the Prospectus may be obtained from the Registrar of Companies in Hong Kong.

任何根據當地法例不得發送、派發或複製本申請表格及招股章程的司法轄區內概不得發送、派發或複製(不論以何種方式，亦不論全部或部分)本申請表格及招股章程。本申請表格及招股章程的副本可從香港公司註冊處索取。本申請表格及招股章程的副本已根據《公司(清盤及雜項條文)條例》第342C條的規定送呈香港公司註冊處登記。香港聯合交易所有限公司(「聯交所」)、香港中央結算有限公司(「香港結算」)、香港證券及期貨監察委員會(「證監會」)及香港公司註冊處處長對此等文件的內容概不負責。

Copies of the Prospectus, all related Application Forms and the other documents specified in “Appendix A – Documents referred to in the Prospectus” to the Prospectus have been registered by the Registrar of Companies in Hong Kong as required by section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the laws of Hong Kong). Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”), Hong Kong Securities Clearing Company Limited (“HKSCC”), the Securities and Futures Commission of Hong Kong (the “SFC”) and the Registrar of Companies of Hong Kong take no responsibility for the contents of these documents.



## Ascentage Pharma Group International 亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)  
(於開曼群島註冊成立的有限公司)

Stock Code : 6555  
股份代號 : 6555

Maximum Offer Price (subject to a Downward Offer Price Adjustment) : HK\$54.20 per Offer Share plus brokerage of 1% SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund) (If the Offer Price is set at 10% below the bottom end of the indicative Offer Price range after making a Downward Offer Price Adjustment, the Offer Price will be HK\$29.00 per Offer Share)

最高發售價(可視乎下調發售價調整予下調調整)

每股發售股份34.20港元，另加1%經紀佣金、0.0027%證監會交易徵費及0.005%聯交所交易費(須於申請時以港元繳足且多繳股款將予退還)(倘作出下調發售價調整後，發售價定於指示性發售價範圍下限10%以下，每股發售股份發售價將為29.00港元)

You should read this Application Form in conjunction with the Prospectus, which contains further information on the application procedures.

招股章程載有申請手續的進一步資料，本申請表格應與招股章程一併閱讀。

### Application Form 申請表格

To: Ascentage Pharma Group International  
The Joint Sponsors  
The Joint Representatives  
The Hong Kong Underwriters

致：亞盛醫藥集團  
聯席保薦人  
聯席代表  
香港包銷商

#### Applicants' declaration

I/We agree to the terms and conditions and application procedures in this Application Form and the Prospectus. Please refer to the “Effect of completing and submitting this Application Form” section of this Application Form.

#### 申請人聲明

本人/吾等同意本申請表格及招股章程的條款及條件以及申請手續。請參閱本申請表格「填寫及遞交本申請表格的效用」一節。

Warning: Only one application may be made for the benefit of any person. Please refer to the last four bullets of “Effect of completing and submitting this Application Form” section.

警告：僅可就任何人士的利益作出一份申請。請參閱「填寫及遞交本申請表格的效用」一節最後四點。

Please use this form if you want the Hong Kong Offer Shares to be issued in the name of HKSCC Nominees Limited (“HKSCC Nominees”) and deposited directly into the Central Clearing and Settlement System (“CCASS”) for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant 如閣下欲以香港中央結算(代理人)有限公司(「香港結算代理人」)的名義登記將獲發行的香港發售股份，並直接存入中央結算及交收系統(「中央結算系統」)，以寄存於閣下的中央結算系統投資者戶口持有人股份戶口或閣下指定的中央結算系統參與者股份戶口，請使用本表格

Signed by (all) applicant(s) (all joint applicants must sign):  
由(所有)申請人簽署(所有聯名申請人必須簽署):

Date: 日期: ..... / ..... / .....  
D 日 M 月 Y 年

Number of Hong Kong Offer Shares applied for (not more than 609,100 Shares)  
請香港發售股份數目(不超過 609,100 股股份)

--

Total amount 總額

HK\$	港元
------	----

Name in English (in BLOCK letter) 英文姓名/名稱(正楷)

Family name or company name 姓氏或公司名稱
-------------------------------------

Name in Chinese 中文姓名/名稱

Family name or company name 姓氏或公司名稱
-------------------------------------

Occupation in English 職業(以英文填寫)

--

Names of all other joint applicants in English (if any, in BLOCK letter)  
所有其他聯名申請人的英文姓名/名稱(如有,正楷)

(1)
(2)
(3)

Hong Kong address in English and telephone no. (joint applicants should give the address and the telephone number of first-named applicant only, in BLOCK letter)  
香港地址(以英文填寫)及電話號碼(聯名申請人只須填寫排名首位申請人的地址及電話號碼)

--

For nominees: You will be treated as applying for your own benefit if you do not complete this section. Please provide an account identification code for each (joint) beneficial owner. 由代名人遞交閣下若不填寫本節，是項申請將視作為閣下本身利益提出。請填寫每名(聯名)實益擁有人的賬戶號碼或識別編碼

--

ADDRESS LABEL 地址標貼 (Your name(s) and address in Hong Kong in BLOCK letters. 請用正楷填寫姓名/名稱及香港地址)


For internal use 此欄供內部使用

--

For Broker use 此欄供經紀填寫	Lodged by 遞交申請的經紀
Broker No. 經紀號碼	Broker's Chop 經紀印章

Cheque/banker's cashier order number 支票/銀行本票號碼
--

Name of bank on which cheque/Banker's cashier order is drawn (see "How to make your application" section) 現支票/銀行本票的銀行名稱(見「申請手續」一節)
--

Forename(s) 名字
----------------

Forename(s) 名字
----------------

Hong Kong Identity Card No./Passport No./Hong Kong Business Registration No.\* (Please delete as appropriate) 香港身份證號碼/護照號碼/香港商業登記號碼\*(請刪除不適用者)

--

Hong Kong identity card no./passport no./Hong Kong business registration no. of all other joint applicants\* (Please delete as appropriate) 所有其他聯名申請人的香港身份證號碼/護照號碼/香港商業登記號碼\*(請刪除不適用者)

(1)
(2)
(3)

Telephone No. 電話號碼

<b>THIS BOX MUST BE DULY COMPLETED</b> 必須填妥此欄
<b>Participant I.D. of the CCASS Investor Participant or designated CCASS Participant</b> 中央結算系統投資者戶口持有人或指定中央結算系統參與者的參與者編號

--

For designated CCASS Participant or Corporate CCASS Investor Participant, please also affix the company chop bearing its company name 指定中央結算系統參與者或公司中央結算系統投資者戶口持有人，請加蓋顯示公司名稱的公司印章

--

(See paragraph 2 in the section “How to make your application”)  
(請參閱「申請手續」一節第 2 段)

Please use this form if you want the Hong Kong Offer Shares to be issued in the name of HKSCC Nominees Limited (“HKSCC Nominees”) and deposited directly into the Central Clearing and Settlement System (“CCASS”) for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant 如閣下欲以香港中央結算(代理人)有限公司(「香港結算代理人」)的名義登記將獲發行的香港發售股份，並直接存入中央結算及交收系統(「中央結算系統」)，以寄存於閣下的中央結算系統投資者戶口持有人股份戶口或閣下指定的中央結算系統參與者股份戶口，請使用本表格

\*(1) If you are a CCASS Investor Participant, only a Hong Kong identity card number (if you are an individual) or a Hong Kong business registration number (if you are a body corporate) will be accepted for this application, please see paragraph 2 under the section “How to make your application”.

如閣下為中央結算系統投資者戶口持有人，是項申請僅接納香港身份證號碼(如屬個人)或香港商業登記號碼(如屬法人團體)，請參閱「申請手續」一節第2段。

(2) If you are applying through a designated CCASS Participant (other than a CCASS Investor Participant) or an individual, you must provide your Hong Kong identity card number or passport number. If you hold a Hong Kong identity card, please provide that number. If you do not hold a Hong Kong identity card, please provide your passport number. For a body corporate, please provide your Hong Kong business registration number.

如閣下透過中央結算系統投資者戶口持有人以外的指定中央結算系統參與者提出申請：如屬個人，必須填寫閣下的香港身份證號碼或護照號碼(持有香港身份證者請填寫香港身份證號碼，否則請填寫護照號碼)；如屬法人團體，請填寫香港商業登記號碼。

(3) Part of the Hong Kong identity card number/passport number of you (for joint applicants, the first-named applicant may be printed on your refund cheque (if any)). Such data will be used for checking the validity of Application Form and such data would also be transferred to a third party for such purpose and refund purpose. Your banker may require verification of your Hong Kong identity card number/passport number before you can cash your refund cheque.

退款支票(如有)上或會印有閣下或(如屬聯名申請人)排名首位申請人的香港身份證號碼/護照號碼的一部分。有關資料將用於核實申請表格是否有效，亦會轉交第三方作資料核實和退款。銀行兌現退款支票前或會要求查核閣下的香港身份證號碼/護照號碼。

(4) If an application is made by an unlisted company and:

- the principal business of the company is dealing in securities; and
- you exercise statutory control over that company,

then the application will be treated as being made for your benefit.

如申請人是一家非上市公司，而：

- 該公司的主要業務為證券買賣；及
  - 閣下可對該公司行使法定控制權，
- 則項申請將作為閣下的利益提出。

(5) All joint applicants must give (if they are individuals) their Hong Kong identity card numbers or, where applicable, passport numbers, or (if they are bodies corporate) their Hong Kong business registration numbers.

所有聯名申請人必須提供(如屬個人)其香港身份證號碼或(如適用)護照號碼，或(如屬法人團體)其香港商業登記號碼。

Sample 樣版

---

This page is intentionally left blank  
此乃白頁，特意留空

---

**Please use this form if you want the Hong Kong Offer Shares to be issued in the name of HKSCC Nominees Limited (“HKSCC Nominees”) and deposited directly into the Central Clearing and Settlement System (“CCASS”) for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant**

### How to make your application

- Use the table below to calculate how much you must pay. Your application must be for a minimum of 100 Hong Kong Offer Shares and in one of the numbers set out in the table, or your application will be rejected.

NUMBER OF SHARES THAT MAY BE APPLIED FOR AND PAYMENTS					
No. of Hong Kong Offer Shares applied for	Amount payable on application (HK\$)	No. of Hong Kong Offer Shares applied for	Amount payable on application (HK\$)	No. of Hong Kong Offer Shares applied for	Amount payable on application (HK\$)
100	3,454.46	5,000	172,723.17	90,000	3,109,011.01
200	6,908.92	6,000	207,267.80	100,000	3,454,463.34
300	10,363.39	7,000	241,812.43	200,000	6,908,926.68
400	13,817.85	8,000	276,357.06	300,000	10,363,390.02
500	17,272.32	9,000	310,901.70	400,000	13,817,853.36
600	20,726.78	10,000	345,446.33	500,000	17,272,316.70
700	24,181.25	20,000	690,892.67	600,000	20,726,780.04
800	27,635.71	30,000	1,036,339.00	609,000*	21,041,136.20
900	31,090.17	40,000	1,381,785.34		
1,000	34,544.63	50,000	1,727,231.67		
2,000	69,089.27	60,000	2,072,678.00		
3,000	103,633.90	70,000	2,418,124.34		
4,000	138,178.53	80,000	2,763,570.67		

\* Maximum number of the Hong Kong Offer Shares you may apply for

- You, as the applicant(s), must complete the form in English in BLOCK letter as indicated below and sign on the second page of the Application Form. Only written signatures will be accepted (and not by way of personal chop).

If you are applying through a designated CCASS Participant (other than a CCASS Investor Participant):

- the designated CCASS Participant must endorse the form with its company chop (bearing its company name) and insert its Participant I.D. in the appropriate box.

If you are applying as an individual CCASS Investor Participant:

- the form must contain your NAME and Hong Kong identity card number;
- your participant I.D. must be inserted in the appropriate box.

If you are applying as a joint individual CCASS Investor Participant:

- the form must contain all joint investor participants' NAMES and the Hong Kong identity card number of each investor participants;
- your participant I.D. must be inserted in the appropriate box.

If you are applying as a corporate CCASS Investor Participant:

- the form must contain your company NAME and Hong Kong business registration number;
- your participant I.D. and your company chop (bearing your company name) must be inserted in the appropriate box.

Incorrect or omission of details of the CCASS Participant including participant I.D. and/or company chop bearing its company name or other similar matters may render your application invalid.

- Staple your cheque or banker's cashier order to the form. Each application for the Hong Kong Offer Shares must be accompanied by either one separate cheque or one separate banker's cashier order. Your application will be rejected if your cheque or banker's cashier order does not meet all the following requirements:



**Please use this form if you want the Hong Kong Offer Shares to be issued in the name of HKSCC Nominees Limited (“HKSCC Nominees”) and deposited directly into the Central Clearing and Settlement System (“CCASS”) for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant**

The cheque must:	Banker’s cashier order must:
<ul style="list-style-type: none"> <li>• be in Hong Kong dollars;</li> <li>• not be post-dated;</li> <li>• be made payable to <b>“BANK OF CHINA (HONG KONG) NOMINEES LIMITED – ASCENTAGE PHARMA PUBLIC OFFER”</b>;</li> <li>• be crossed “Account Payee Only”;</li> </ul>	
<ul style="list-style-type: none"> <li>• be drawn on your Hong Kong dollar bank account in Hong Kong; and</li> <li>• show your account name, which must either be pre-printed on the cheque, or be endorsed on the back by a person authorized by the bank. This account name must correspond with your name. If it is a joint application, the account name must be the same as the first-named applicant’s name.</li> </ul>	<ul style="list-style-type: none"> <li>• be issued by a licensed bank in Hong Kong and have your name certified on the back by a person authorized by the bank. The name on the banker’s cashier order must correspond with your name. If it is a joint application, the name on the back of the banker’s cashier order must be the same as the first-named applicant’s name.</li> </ul>

4. Tear off the Application Form, fold it once and lodge your completed Application Form (with cheque or banker’s cashier order attached) to one of the collection desks at any of the following branches of:

**Bank of China (Hong Kong) Limited**

	<b>Branch Name</b>	<b>Address</b>
<b>Hong Kong Island</b>	South Horizons Branch	Shop G13 & G15, G/F, Marina Square, West Commercial Block, South Horizons, Ap Lei Chau, Hong Kong
	Wan Chai (Yu Chu) Branch	213 Queen’s Road East, Wan Chai, Hong Kong
<b>Kowloon</b>	Lam Tin Branch	Shop 12, 49 Kai Tin Road, Lam Tin, Kowloon
	Kowloon Plaza Branch	Unit 1, Kowloon Plaza, 485 Castle Peak Road, Kowloon
<b>New Territories</b>	Yuen Long Branch	102-108 Castle Peak Road, Yuen Long, New Territories
	Metro City Branch	Shop 209, Level 2, Metro City Phase 1, Tseung Kwan O, New Territories

5. Your Application Form can be lodged at these times:

**Wednesday, October 16, 2019 — 9:00 a.m. to 5:00 p.m.**  
**Thursday, October 17, 2019 — 9:00 a.m. to 5:00 p.m.**  
**Friday, October 18, 2019 — 9:00 a.m. to 5:00 p.m.**  
**Monday, October 21, 2019 — 9:00 a.m. to 12:00 noon**

6. The latest time for lodging your application is 12:00 noon on Monday, October 21, 2019. The application lists will be open between 11:45 a.m. and 12:00 noon on that day, subject only to the weather conditions, as described in “C. Effect of Bad Weather on the Opening and Closing of the Application Lists” in the “How to Apply for the Hong Kong Offer Shares” section of the Prospectus.

如閣下欲以香港中央結算(代理人)有限公司(「香港結算代理人」)的名義登記將獲發行的香港發售股份，並直接存入中央結算及交收系統(「中央結算系統」)，以寄存於閣下的中央結算系統投資者戶口持有人股份戶口或閣下指定的中央結算系統參與者股份戶口，請使用本表格

## 申請手續

- 請使用下表計算閣下應付的款項。閣下申請認購的股份數目須至少為100股香港發售股份，並為下表所列的其中一個數目，否則恕不受理。

可供申請認購股份數目及應繳款項					
申請認購的香港發售股份數目	申請時應繳款項(港元)	申請認購的香港發售股份數目	申請時應繳款項(港元)	申請認購的香港發售股份數目	申請時應繳款項(港元)
100	3,454.46	5,000	172,723.17	90,000	3,119,010.01
200	6,908.92	6,000	207,267.80	100,000	45,463.34
300	10,363.39	7,000	241,812.43	200,000	6,922,926.68
400	13,817.85	8,000	276,357.06	300,000	10,363,390.02
500	17,272.32	9,000	310,901.70	400,000	13,817,853.36
600	20,726.78	10,000	345,446.33	500,000	17,272,316.70
700	24,181.25	20,000	690,892.67	600,000	20,726,780.04
800	27,635.71	30,000	1,036,339.01	509,000*	21,041,136.20
900	31,090.17	40,000	1,381,785.35		
1,000	34,544.63	50,000	1,727,231.69		
2,000	69,089.27	60,000	2,072,678.03		
3,000	103,633.90	70,000	2,418,124.37		
4,000	138,178.53	80,000	2,763,570.71		

\* 閣下可申請認購的香港發售股份最高數目。

- 閣下作為申請人，必須按照下列指示以英文正楷填寫表格，並於申請表格第二頁簽署，僅接納親筆簽名(不得以個人印章代替)。

如閣下透過中央結算系統投資者戶口持有人以外的指定中央結算系統參與者提出申請：

- 該指定中央結算系統參與者必須於表格上加蓋公司印章(附有公司名稱)，並在適當方格內填寫參與者編號。

如閣下以個人中央結算系統投資者戶口持有人名義提出申請：

- 表格必須載有閣下的姓名及香港身份證號碼；
- 必須在適當方格內填寫閣下的參與者編號。

如閣下以聯名個人中央結算系統投資者戶口持有人名義提出申請：

- 表格必須載有所有聯名投資者戶口持有人的姓名及所有聯名投資者戶口持有人的香港身份證號碼；
- 必須在適當方格內填寫閣下的參與者編號。

如閣下以公司中央結算系統投資者戶口持有人名義提出申請：

- 表格必須載有閣下的公司名稱及香港商業登記號碼；
- 必須在適當方格內填寫閣下的參與者編號並加蓋公司印章(附有公司名稱)。

中央結算系統參與者的資料(包括參與者編號及/或附有公司名稱的公司印章)或其他類似事項如有錯誤或遺漏，均可能導致申請無效。

- 閣下須將支票或銀行本票釘於表格上。每份香港發售股份申請必須附上一張獨立開出的支票或一張獨立開出的銀行本票。倘支票或銀行本票未符合以下所有規定，閣下的認購申請將不獲接納：

如閣下欲以香港中央結算(代理人)有限公司(「香港結算代理人」)的名義登記將獲發行的香港發售股份，並直接存入中央結算及交收系統(「中央結算系統」)，以寄存於閣下的中央結算系統投資者戶口持有人股份戶口或閣下指定的中央結算系統參與者股份戶口，請使用本表格

支票必須：	銀行本票必須：
<ul style="list-style-type: none"> <li>為港元支票；</li> <li>不得為期票；</li> <li>註明抬頭人為「中國銀行(香港)代理人有限公司－亞盛醫藥公開發售」；</li> <li>劃線註明「只准入抬頭人賬戶」；</li> </ul>	
<ul style="list-style-type: none"> <li>從閣下在香港的港元銀行賬戶中開出；及</li> <li>顯示閣下的賬戶名稱，而該賬戶名稱必須已預印在支票上，或由有關銀行授權的人士在支票背書。賬戶名稱必須與閣下姓名／名稱相同。如屬聯名申請，賬戶名稱必須與排名首位申請人的姓名／名稱相同。</li> </ul>	<ul style="list-style-type: none"> <li>須由香港持牌銀行開出，並由有關銀行授權的人士在銀行本票背面簽署及蓋印姓名／名稱。銀行本票所列姓名／名稱須與閣下姓名／名稱相同。如屬聯名申請，銀行本票背面所列姓名／名稱必須與排名首位申請人的姓名／名稱相同。</li> </ul>

4. 請撕下申請表格，對摺一次，然後將填妥的申請表格連同隨附支票(銀行本票)投入下列任何一家分行的收集箱：

#### 中國銀行(香港)有限公司

	分行名稱	地址
香港島	海怡分行	香港鴨脷洲海怡廣場西翼 G13 及 G15 舖
	灣仔胡忠大廈分行	香港灣仔皇后大道東 213 號
九龍	藍田分行	九龍藍田啟田道 49 號 12 號舖
	九龍廣場分行	九龍青山道 485 號九龍廣場 1 號
新界	元朗分行	新界元朗青山公路 102-108 號
	新都城分行	新界將軍澳新都城一期二樓 209 號

5. 閣下可於下列時間遞交申請表格：

二零一九年十月十六日(星期三)	－ 上午九時正至下午五時正
二零一九年十月十七日(星期四)	－ 上午九時正至下午五時正
二零一九年十月十八日(星期五)	－ 上午九時正至下午五時正
二零一九年十月二十一日(星期一)	－ 上午九時正至中午十二時正

6. 閣下遞交申請的最後時間為二零一九年十月二十一日(星期一)中午十二時正。本公司將於當日上午十一時四十五分至中午十二時正期間登記認購申請，惟須視乎當日的天氣情況(詳見招股章程「如何申請香港發售股份」一節「C. 惡劣天氣對開始及截止申請登記的影響」)。



Please use this form if you want the Hong Kong Offer Shares to be issued in the name of HKSCC Nominees Limited (“HKSCC Nominees”) and deposited directly into the Central Clearing and Settlement System (“CCASS”) for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant



## Ascentage Pharma Group International

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

### GLOBAL OFFERING

#### Conditions of your application

##### A. Who can apply

1. You and any person(s) for whose benefit you are applying must be 18 years of age or older and must have a Hong Kong address.
2. If you are a firm, the application must be in the individual members’ names.
3. The number of joint applicants may not exceed four.
4. If you are a body corporate, the application must be signed by a duly authorized officer, who must state his representative capacity, and stamped with your corporation’s chop.
5. You must be outside the United States, not be a United States Person (as defined in Regulation S under the U.S. Securities Act) or are a person described in paragraph (h)(3) of Rule 902 of Regulation S and not be a legal or natural person of the PRC.
6. Unless permitted by the Listing Rules, you cannot apply for any Hong Kong Offer Shares if you:
  - are an existing beneficial owner of shares in the Company and/or any of its subsidiaries;
  - are a Director or chief executive of the Company and/or its subsidiaries;
  - are a connected person (as defined in the Listing Rules) of the Company or will become a core connected person of the Company immediately upon completion of the Global Offering;
  - an associate (as defined in the Listing Rules) of any of the above; or
  - have been allocated or have applied for or indicated an interest in any International Offer Shares or otherwise participate in the International Offering.

##### B. If you are a nominee

You, as a nominee, may make more than one application for the Hong Kong Offer Shares by: (i) giving electronic instructions to HKSCC via Central Clearing and Settlement System (“CCASS”) (if you are a CCASS Participant); or (ii) using a WHITE ELEPHANT Application Form, and lodge more than one application in your own name on behalf of different beneficial owners.

##### C. Completing and submitting this Application Form

By completing and submitting this Application Form, you (and if you are joint applicants, each of you jointly and severally) for yourself or as an agent or a nominee on behalf of each person for whom you act:

- undertake to execute all relevant documents and instruct and authorize the Company and/or the Joint Representatives (or their agents or nominees), as agents of the Company, to execute any documents for you and to do on your behalf all things necessary to register any Hong Kong Offer Shares allocated to you in the name of HKSCC Nominees as required by the Articles of Association;
- agree to comply with the Articles of Association, the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong) and the Cayman Islands Companies Law;
- confirm that you have read the terms and conditions and application procedures set out in the Prospectus and in this Application Form and agree to be bound by them;

- confirm that you have received and read the Prospectus and have only relied on the information and representations contained in the Prospectus in making your application and will not rely on any other information or representation, except those expressly supplement to the Prospectus;
- confirm that you are aware of the restrictions on the Global Offering in the Prospectus;
- agree that the Company and the Relevant Persons is or will be liable for the information and representations not in the Prospectus and any supplement;
- warrant and confirm that you or the person(s) for whose benefit you have made the application have not applied for or taken up, or indicated an interest in, and will not apply for or take up, or indicate an interest in, any International Offer Shares nor participate in the International Offering;
- agree to disclose to the Company, the Hong Kong Share Registrar, the receiving banks and the Relevant Persons any personal data which they may require about you and the person(s) for whose benefit you have made the application;
- if the laws of any place outside Hong Kong apply to your application, agree and warrant that you have complied with all such laws and neither the Company nor the Relevant Persons will breach any law outside Hong Kong as a result of the acceptance of your offer to purchase, or any action arising from your rights and obligations under the terms and conditions contained in the Prospectus and this Application Form;
- agree that once your application has been accepted, you may not rescind it because of an innocent misrepresentation;
- agree that your application will be governed by the laws of Hong Kong;
- represent, warrant and undertake that (i) you understand that the Hong Kong Offer Shares have not been and will not be registered under the U.S. Securities Act; and (ii) you and any person for whose benefit you are applying for the Hong Kong Offer Shares are outside the United States (within the meaning of Regulation S) or are a person described in paragraph (h)(3) of Rule 902 of Regulation S;
- warrant that the information you have provided is true and accurate;
- agree to accept the Hong Kong Offer Shares applied for or any lesser number allocated to you under the application;
- authorize (i) the Company to place the name of the HKSCC Nominees on the Company’s register of members as the holder(s) of any Hong Kong Offer Shares allocated to you and such other registers as required under the Articles of Association, and (ii) the Company and/or its agents to deposit any Share certificate(s) into CCASS and/or to send any e-Auto Refund payment instructions and/or any refund cheque(s) to you or the first-named applicant for joint application by ordinary post at your own risk to the address stated on the application, unless you have chosen to collect refund cheque(s) in person;
- agree that the Hong Kong Offer Shares to be allotted shall be issued in the name of HKSCC Nominees and deposited directly into CCASS for credit to your investor participant stock account or the stock account of your designated CCASS Participant;

**Please use this form if you want the Hong Kong Offer Shares to be issued in the name of HKSCC Nominees Limited (“HKSCC Nominees”) and deposited directly into the Central Clearing and Settlement System (“CCASS”) for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant**

- agree that each of HKSCC and HKSCC Nominees reserves the right (1) not to accept any or part of such allotted Shares issued in the name of HKSCC Nominees or not to accept such allotted Shares for deposit into CCASS; (2) to cause such allotted Shares to be withdrawn from CCASS and issued in your name at your own risk and costs; and (3) to cause such allotted Shares to be issued in your name (or, if you are a joint applicant, to the first-named applicant) and in such a case, to post the certificates for such allotted Shares at your own risk to the address on your application form by ordinary post or to make available the same for your collection;
- agree that each of HKSCC and HKSCC Nominees may adjust the number of allotted Shares issued in the name of HKSCC Nominees;
- agree that neither HKSCC nor HKSCC Nominees shall have any liability for the information and representations not so contained in the Prospectus and this Application Form;
- agree that neither HKSCC nor HKSCC Nominees shall be liable to you in any way;
- declare and represent that this is the only application made and the only application intended by you to be made to benefit you or the person for whose benefit you are applying;
- understand that the Company, the Directors and the Joint Representatives will rely on your declarations and representations in deciding whether or not to allocate any of the Hong Kong Offer Shares to you and that you may be prosecuted for making a false declaration;
- (if the application is made for your own benefit) warrant that no other application has been or will be made for your benefit on a **WHITE** or **YELLOW** Application Form or by giving **electronic application instructions** to HKSCC or through the **HK eIPO White Form** service by you or by any one as your agent or by any other person; and
- (if you are making the application as an agent for the benefit of another person) warrant that (i) no other application has been or will be made by you as agent for or for the benefit of that person or by that person or by any other person as agent for that person on a **WHITE** or **YELLOW** Application Form or by giving **electronic application instructions** to HKSCC; and (ii) you have the authority to sign the Application Form or give **electronic application instructions** on behalf of that other person as their agent.

**D. Power of attorney**

If your application is made through an authorised attorney, the Company and the Joint Representatives, may accept or process your application at their discretion and on any conditions they think fit, including requiring evidence of the attorney’s authority.

**Price Determination of the Global Offering**

The Offer Price is expected to be fixed on or before Monday, October 21, 2019. Applicants are required to pay the maximum Offer Price of HK\$34.20 for each Hong Kong Offer Share together with brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%. If the Offer Price is not agreed between the Company and the Joint Representatives (for themselves and on behalf of the Underwriters) by Tuesday, October 22, 2019, the Global Offering will not proceed and will lapse. Applications for Hong Kong Offer Shares will not be processed and allotment of any Hong Kong Offer Shares will be made until the application list is closed.

If the Company decides to reduce the Offer Price by making a Downward Offer Price Adjustment (a reduction of up to 10% below the bottom end of the indicative Offer Price range), the Company will separately announce the final Offer Price no later than Tuesday, October 22, 2019 on the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) and the Company’s website at [www.ascentagepharma.com](http://www.ascentagepharma.com).

**Publication of results**

Irrespective of whether a Downward Offer Price Adjustment is made, the Company expects to announce the Offer Price, the level of indication of interest in the International Offering, the level of applications under the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares on or before Friday, October 25, 2019 in the South China Morning Post (in English) and the Hong Kong Economic Times (in Chinese) and on the websites of the Company at [www.ascentagepharma.com](http://www.ascentagepharma.com) and the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk). The results of allocations in the Hong Kong Public Offering, and the Hong Kong identity card/passport/Hong Kong business registration numbers of successful applicants (where applicable) will be available on the above websites.

**Allocation of Offer Shares**

The allocation of Offer Shares between the Hong Kong Public Offering and the International Offering is subject to reallocation as described in the section headed “Structure and Conditions of the Global Offering” in the Prospectus. In particular, the Joint Representatives (for themselves and on behalf of the Underwriters) and the Joint Sponsors shall have the right to reallocate Offer Shares from the International Offering to the Hong Kong Public Offering. In accordance with Guidance Letter HKEX-GL91-18 issued by the Stock Exchange, if such reallocation is done other than pursuant to Practice Note 18 of the Listing Rules, the maximum total number of Offer Shares under the Hong Kong Public Offering following such reallocation shall be not more than 2,000,000 Offer Shares. Further details on the circumstances under which the reallocation letter would apply are set out in the section titled “Structure and Conditions of the Global Offering” in the Prospectus.

**If your application for Hong Kong Offer Shares is successful (in whole or in part)**

If your application is wholly or partly successful, your share certificate(s) (subject to the becoming valid certificate of title provided that the Hong Kong Public Offering has become unconditional and not having been terminated at 9:00 a.m. on Monday, October 28, 2019) will be issued in the name of HKSCC Nominees and deposited directly into CCASS for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant as instructed by you in your application Form on or before Friday, October 25, 2019 or, in the event of a conflict, on any other date as shall be determined by HKSCC or HKSCC Nominees.

- If you are applying through a designated CCASS Participant (other than a CCASS Investor Participant): For Hong Kong Offer Shares credited to the stock account of your designated CCASS Participant (other than a CCASS Investor Participant), you can check the number of Hong Kong Offer Shares allotted to you with that CCASS Participant.

If you are applying as a CCASS Investor Participant: The Company expects to publish the application results of CCASS Investor Participants’ applications together with the results of the Hong Kong Offer Shares in the South China Morning Post (in English) and the Hong Kong Economic Times (in Chinese), on the Company’s website at [www.ascentagepharma.com](http://www.ascentagepharma.com) and the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) on Friday, October 25, 2019. You should check the announcement published by the Company and report any discrepancies to HKSCC before 5:00 p.m. on Friday, October 25, 2019 or such other date as shall be determined by HKSCC or HKSCC Nominees. Immediately after the credit of the Hong Kong Offer Shares to your stock account you can check your new account balance via the CCASS Phone System and CCASS Internet System (under the procedures contained in HKSCC’s “An Operating Guide for Investor Participants” in effect from time to time). HKSCC will also make available to you an activity statement showing the number of Hong Kong Offer Shares credited to your stock account.

No receipt will be issued for application money paid. The Company will not issue temporary documents of title.

**Refund of application monies**

If you do not receive any Hong Kong Offer Shares or if your application is accepted only in part, the Company will refund to you your application monies, or the appropriate portion thereof, together with brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% without interest. If the Offer Price is less than the maximum Offer Price, the Company will refund to you the surplus application monies together with brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% without interest. The refund procedures are stated in the “Despatch/Collection of Share Certificates and Refund Monies” in the “How to Apply for Hong Kong Offer Shares” section of the Prospectus.

**Effect of the Information You Give to Us**

Tricor Investor Services Limited and its related bodies’ corporate, directors, officers, employees and agents (“Representatives”) expressly disclaim and exclude to the maximum extent permitted by law any liability for any loss or damage suffered or incurred by the applicant or any other person or entity however caused relating in any way to, or connected with, any information provided by or on behalf of the applicant on or in connection with this document or any services provided hereunder, or any other written or oral communication provided by or on behalf of the applicant in connection with this document or any services provided hereunder. This includes, without limitation, any errors or omissions in such information however caused, or the Representatives or any other person or entity placing any reliance on such information or any documentation, image, recording or reproduction of such information, or its accuracy, completeness, currency or reliability.



如閣下欲以香港中央結算(代理人)有限公司(「香港結算代理人」)的名義登記將獲發行的香港發售股份，並直接存入中央結算及交收系統(「中央結算系統」)，以寄存於閣下的中央結算系統投資者戶口持有人股份戶口或閣下指定的中央結算系統參與者股份戶口，請使用本表格



**Ascentage Pharma Group International**  
**亞盛醫藥集團**  
(於開曼群島註冊成立的有限公司)

**全球發售**

**申請條件**

**甲. 可提出申請的人士**

- 閣下及閣下為其利益提出申請的任何人士必須年滿18歲並擁有香港地址。
- 如閣下為商號，申請必須以個人成員名義提出。
- 聯名申請人不得超過四名。
- 如閣下為法人團體，申請須經獲正式授權人士簽署，並註明其代表身份及加蓋公司印章。
- 閣下必須身處美國境外，且非美籍人士(定義見美國證券法下的S規例)或屬S規例第902條第(h)(3)段所述的人士，且並非中國法人或自然人。
- 除非上市規則允許，否則下列人士不得申請任何香港發售股份：
  - 本公司及/或其任何附屬公司股份的現有實益擁有人；
  - 本公司及/或其附屬公司的董事或行政總裁；
  - 本公司關連人士(定義見上市規則)或緊隨全球發售完成後將成為本公司核心關連人士的人士；
  - 上述任何人士的聯繫人(定義見上市規則)；或
  - 已獲分配或已申請或表示有意申請任何國際發售股份或以其他方式參與國際發售

**乙. 如閣下為代名人**

閣下作為代名人可提出超過一份香港發售股份申請。方法是：(i)透過中央結算及交收系統(「中央結算系統」)由香港結算發出電子認購指示(如閣下為中央結算系統參與者)；或(ii)使用白色或黃色申請表格以個人名義代表不同實益擁有人提交超過一份申請。

**丙. 填寫及遞交本申請表格的效力**

閣下填寫及遞交本申請表格，即表示閣下(如屬聯名申請人，即各大股東及個別)代表閣下本身，或作為閣下代其行事的每名人士的代理或代名人：

- 承諾簽立所有有關文件，並指示及授權本公司及/或其代理或代名人，代表閣下簽立任何文件，並代表閣下處理一切必要事務，以便根據組織章程細則的規定，以香港結算代理人的名義登記閣下獲分配的任何香港發售股份；
- 同意遵守組織章程細則、香港法例第622章《公司條例》、香港法例第32章《公司(清盤及雜項條文)條例》及開曼群島公司法；
- 確認閣下已閱讀招股章程及本申請表格所載條款及條件以及申請手續，並同意受其約束；
- 確認閣下已接獲及閱讀招股章程，並於作出申請時僅倚賴招股章程所載資料及陳述，且將不會倚賴招股章程任何補充文件所載者以外的任何其他資料或陳述；
- 確認閣下已知悉招股章程內有關全球發售的限制；
- 同意本公司及有關人士均不會或將不會對招股章程(及其任何補充文件)所載者之外的任何資料及陳述負責；

- 承諾及確認閣下及閣下為其利益提出申請的人士並無申請或認購或表示有意申請或認購任何國際發售股份，亦將不會申請或認購或表示有意申請或認購任何國際發售股份，亦不會參與任何國際發售；
- 同意向本公司、香港證券登記處、收銀銀行及相關人士披露閣下及閣下為其利益提出申請的人士的個人資料；
- 若香港以外任何地區的例適用於閣下的申請，則並閣下同意及保證閣下已遵守所有有關法例，且本公司及有關人士將不會因接納閣下的購買要約或因閣下於招股章程及本申請表格所載條款及條件項下的權利與義務所引伸的任何行動而違反香港以外地區的任何法例；
- 同意閣下的申請一經接納，即不得因無意作出的失實陳述而撤銷申請；
- 同意閣下的申請受香港法例規管；
- 保證及承諾(i)閣下明白香港發售股份並無及將不會根據美國證券法登記；及(ii)閣下及閣下為其利益申請香港發售股份的任何人士均身處美國境外(定義見S規例)，或屬S規例第902條第(h)(3)段所述的人士；
- 保證閣下所提供的資料真實準確；
- 同意接納所申請的香港發售股份或根據申請向閣下所分配任何較少數目的股份；
- 授權(i)本公司將香港結算代理人的名稱列入本公司股東名冊及組織章程細則規定之其他名冊，作為閣下獲分配任何香港發售股份的持有人，及(ii)本公司及/或其代理將任何股票存入中央結算系統及/或將任何電子自動退款指示及/或任何退款支票以普通郵遞方式按申請所示地址寄予閣下或(如屬聯名申請)排名首位的申請人，郵誤風險概由閣下自行承擔，除非閣下已選擇親身領取退款支票；
- 同意將獲配發的香港發售股份以香港結算代理人的名義發行，並直接存入中央結算系統，以寄存於閣下的投資者戶口持有人股份戶口或閣下指定的中央結算系統參與者股份戶口；
- 同意香港結算及香港結算代理人均保留權利，(1)不接納以香港結算代理人名義發行的該等獲配發股份的全部或部分，或不接納該等獲配發股份存入中央結算系統；(2)促使該等獲配發股份從中央結算系統提取，並轉入閣下名下，有關風險及費用概由閣下自行承擔；及(3)促使該等獲配發股份以閣下名義發行(或如屬聯名申請人，則以排名首位申請人的名義發行)，而在此情況下，會以普通郵遞方式將該等獲配發股份的股票寄往閣下在申請表格上所示地址(郵誤風險概由閣下自行承擔)或提供該等股票供閣下領取；

如閣下欲以香港中央結算(代理人)有限公司(「香港結算代理人」)的名義登記將獲發行的香港發售股份，並直接存入中央結算及交收系統(「中央結算系統」)，以寄存於閣下的中央結算系統投資者戶口持有人股份戶口或閣下指定的中央結算系統參與者股份戶口，請使用本表格

- 同意香港結算及香港結算代理人均可調整以香港結算代理人名義發行的獲配發股份數目；
- 同意香港結算及香港結算代理人對招股章程及本申請表格未有載列的資料及陳述概不負責；
- 同意香港結算及香港結算代理人概不以任何方式對閣下負責；
- 聲明及表示此乃閣下作出的唯一申請及閣下擬以本身或閣下為其利益提出申請的人士為受益人作出的唯一申請；
- 明白本公司、董事及聯席代表將倚賴閣下的聲明及陳述以決定是否向閣下分配任何香港發售股份及閣下如作出虛假聲明，則可能會被檢控；
- (如申請以閣下本身為受益人提出)保證閣下或閣下任何代理或任何其他人士並無及將不會為閣下的利益而以白色或黃色申請表格或向香港結算或通過網上白表服務發出電子認購指示而作出其他申請；及
- (如閣下作為代理為其他人士利益提出申請)保證(i) 閣下(作為該名人士的代理或為其利益)或該名人士或作為其代理的任何其他人士並無及將不會以白色或黃色申請表格或向香港結算發出電子認購指示作出其他申請；及(ii) 閣下已獲正式授權以該名其他人士代理的身份簽署申請表格或發出電子認購指示。

#### 丁. 授權書

如閣下的申請由正式授權的代表提出，本公司及聯席代表可按其認為合適的任何條件(包括要求出示授權證明)的情況接納或拒絕閣下的申請。

#### 全球發售定價

預期發售價將於二零一九年十月二十一日(星期一)或之後釐定。申請人須繳付最高發售價每股香港發售股份34.50港元，另加1%經紀佣金、0.0027%證監會交易徵費及0.005%聯交所交易費。倘本公司與聯席代表(為彼等本身及代表包銷商)並無於二零一九年十月二十二日(星期二)之前協定發售價，全球發售將不會進行並將失效。在正式登記申請前，不會處理香港發售股份的申請或接受任何香港發售股份。

倘本公司決定按下調發售價(最多降於指示性發售價範圍下限10%以下)降低發售價，本公司將在不遲於二零一九年十月二十二日(星期二)在聯交所網站 [www.hkexnews.hk](http://www.hkexnews.hk) 及本公司網站 [www.ascentagepharma.com](http://www.ascentagepharma.com) 另行發表最終發售價公告。

#### 公佈結果

不管是否進行發售價調整，本公司預期於二零一九年十月二十五日(星期五)或之前在南華早報(以英文)、香港經濟日報(以中文)及本公司網站 [www.ascentagepharma.com](http://www.ascentagepharma.com) 及聯交所網站 [www.hkexnews.hk](http://www.hkexnews.hk) 公佈發售價、國際發售踴躍程度、香港公開發售的申請數量及香港發售股份的分配基準。香港公開發售的分配結果及獲接納申請人的香港身份證/護照/香港商業登記號碼(如適用)亦將於上述網站公佈。

#### 分配發售股份

發售股份在香港公開發售與國際發售之間的分配視乎招股章程「全球發售的架構及條件」一節所述的重新分配而定。特別是，聯席代表(為彼等本身及代表包銷商)及聯席保薦人有權將發售股份由國際發售重新分配至香港公開發售。根據聯交所發佈的指引信 HKEx-GL91-18，倘並非根據上市規則第18項應用指引進行重新分配，則於有關重新分配後香港公開發售的發售股份總數最多不得超過2,436,400股

發售股份。有關以上指引信將適用的情況的進一步詳情載於招股章程「全球發售的架構及條件」一節。

#### 如閣下的香港發售股份申請獲接納(全部或部分)

如閣下的申請全部或部分獲接納，閣下的股票(前提是在香港公開發售已成為無條件且並未終止的情況下，股票於二零一九年十月二十八日(星期一)上午八時正成為有效的所有權證明)將以香港結算代理人名義發行，並按閣下在申請表格的指示於二零一九年十月二十五日(星期五)或(在特別情況下)由香港結算或香港結算代理人指定的任何其他日期直接存入中央結算系統，以寄存於閣下的中央結算系統投資者戶口持有人股份戶口或閣下指定的中央結算系統參與者股份戶口。

- 如閣下透過中央結算系統投資者戶口持有人以外的指定中央結算系統參與者提出申請，香港發售股份寄存於閣下指定的中央結算系統參與者(非中央結算系統投資者戶口持有人)股份戶口，閣下可向該中央結算系統參與者查詢閣下獲配發的香港發售股份數目。
- 如閣下以中央結算系統投資者戶口持有人身份提出申請，本公司預期於二零一九年十月二十五日(星期五)在南華早報(以英文)、香港經濟日報(以中文)、本公司網站 [www.ascentagepharma.com](http://www.ascentagepharma.com) 及聯交所網站 [www.hkexnews.hk](http://www.hkexnews.hk) 公佈中央結算系統投資者戶口持有人的申請結果及香港發售股份的結果。閣下應查閱本公司刊發的公佈，如有任何資料不符，請於二零一九年十月二十五日(星期五)或香港結算或香港結算代理人決定的該等其他日期下午五時正前知會香港結算。緊隨香港發售股份寄存於閣下的股份戶口後，閣下即可透過「結算通」電話系統及中央結算系統互聯網系統(根據香港結算不時有效的「投資者戶口操作簡介」所載程序)查詢閣下的新戶口結餘。香港結算亦將向閣下提供一份活動結單，列出寄存於閣下股份戶口的香港發售股份數目。

本公司不會就申請時繳付的款項發出收據，亦不會發出臨時所有權文件。

#### 退還申請股款

若閣下未獲分配任何香港發售股份或申請僅部分獲接納，本公司將不計利息退還閣下的申請股款或其適當部分連同相關的1%經紀佣金、0.0027%證監會交易徵費及0.005%聯交所交易費。如發售價低於最高發售價，本公司將不計利息退還多收申請股款連同相關的1%經紀佣金、0.0027%證監會交易徵費及0.005%聯交所交易費。有關退款手續載於招股章程「如何申請香港發售股份」一節「發送/領取股票及退回股款」。

#### 閣下提供給我們的資訊的有關影響

卓佳證券登記有限公司和其有關連的法人團體、董事、高級人員、僱員及代理人(「代表」)在法律所容許的最大限度內明確卸棄及免除在任何方面與申請人或代表申請人在此文件提供的或與此文件或在此文件下提供的任何服務相關的任何資料，或任何申請人或代表申請人提供與此文件或在此文件下提供的任何服務相關的任何其他書面或口頭通訊，有關或相關由申請人或任何其他人士或實體所遭受或招致不論如何造成的任何損失或損害的任何法律責任。此包括，但不限於，該等資料中不論如何造成的任何錯誤或遺漏，或代表或任何其他人士或實體對該等資料或任何該等資料的文件記錄、影像、記錄或複製品作出的任何依據，或其準確性、完整性、合時性或可靠性。



**Please use this form if you want the Hong Kong Offer Shares to be issued in the name of HKSCC Nominees Limited (“HKSCC Nominees”) and deposited directly into the Central Clearing and Settlement System (“CCASS”) for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant**

## **Personal Data**

### **Personal Information Collection Statement**

This Personal Information Collection Statement informs the applicant for, and holder of, Hong Kong Offer Shares, of the policies and practices of the Company and the Hong Kong Share Registrar in relation to personal data and the Personal Data (Privacy) Ordinance (Chapter 486 of the Laws of Hong Kong) (the “Ordinance”).

#### **1. Reasons for the collection of your personal data**

It is necessary for applicants and registered holders to supply correct personal data to the Company or its agents and the Hong Kong Share Registrar when applying for securities or transferring securities into or out of their names or in procuring the services of the Hong Kong Share Registrar. Failure to supply the requested data may result in your application for securities being rejected, or in delay or the inability of the Company or the Hong Kong Share Registrar to effect transfers or otherwise render their services. It may also prevent or delay registration or transfers of the Hong Kong Offer Shares which you have successfully applied for and/or the despatch of share certificate(s) and/or refund cheque(s) to which you are entitled.

It is important that securities holders inform the Company and the Hong Kong Share Registrar immediately of any inaccuracies in the personal data supplied.

#### **2. Purposes**

The personal data of the securities holders may be held, processed and/or stored (by whatever means) for the following purposes:

- processing your application and refund cheque and e-Refund payment instructions, where applicable, verification of compliance with the terms and application procedures set out in this Application Form and the Prospectus and announcing results of allocation of the Hong Kong Offer Shares;
- compliance with applicable laws and regulations in Hong Kong and elsewhere;
- registering new issues or transfers into or out of securities holders including, where applicable, HKSCC Nominees;
- maintaining or updating the register of securities holders of the Company;
- verifying securities holders’ identities;
- establishing benefit entitlements of securities holders of the Company, such as dividends, rights issues and bonus issues;
- distributing communications from the Company and its subsidiaries;
- compiling statistical information and shareholder profiles;
- disclosing relevant information to facilitate claims on entitlements; and
- any other incidental or associated purposes relating to the above and/or to enable the Company and

the Hong Kong Share Registrar to discharge their obligations to securities holders and/or regulators and/or any other purposes to which the securities holders may from time to time agree.

#### **3. Transfer of personal data**

Personal data held by the Company and the Hong Kong Share Registrar relating to the securities holders will be kept confidential but the Company and the Hong Kong Share Registrar may, to the extent necessary for achieving any of the above purposes, disclose or transfer (whether within or outside Hong Kong) the personal data to any of the following:

- the Company’s appointed agents such as financial advisers, clearing bank and overseas principal shareholders;
- where applicants for securities request a deposit into CCASS, HKSCC or HKSCC Nominees, we will use the personal data for the purposes of operating CCASS;
- any agents, contractors or third-party service providers who offer administrative, telecommunications, computer, payment or other services to the Company or the Hong Kong Share Registrar in connection with their respective business operation;
- the Stock Exchange, the SFC and any other statutory regulatory or governmental bodies or otherwise as required by laws, rules or regulations; and
- any persons or institutions with which the securities holders have or propose to have dealings, such as their bankers, solicitors, accountants or stockbrokers etc.

#### **4. Retention of personal data**

The Company and the Hong Kong Share Registrar will keep the personal data of the applicants and holders of securities for as long as necessary to fulfil the purposes for which the personal data were collected. Personal data which is no longer required will be destroyed or dealt with in accordance with the Ordinance.

#### **5. Access to and correction of personal data**

Securities holders have the right to ascertain whether the Company or the Hong Kong Share Registrar hold their personal data, to obtain a copy of that data, and to correct any data that is inaccurate. The Company and the Hong Kong Share Registrar have the right to charge a reasonable fee for the processing of such requests.

All requests for access to data or correction of data should be addressed to us, at our registered address disclosed in the “Corporate Information” section of the Prospectus or as notified from time to time, for the attention of the company secretary, or the Hong Kong Share Registrar for the attention of the privacy compliance officer.

**By signing an Application Form or by giving electronic application instructions to HKSCC, you agree to all of the above.**



如閣下欲以香港中央結算(代理人)有限公司(「香港結算代理人」)的名義登記將獲發行的香港發售股份，並直接存入中央結算及交收系統(「中央結算系統」)，以記存於閣下的中央結算系統投資者戶口持有人股份戶口或閣下指定的中央結算系統參與者股份戶口，請使用本表格

## 個人資料

### 個人資料收集聲明

此項個人資料收集聲明是向香港發售股份的申請人及持有人說明本公司及香港證券登記處有關個人資料及香港法例第486章《個人資料(私隱)條例》(「條例」)方面的政策及常規。

#### 1. 收集閣下個人資料的原因

申請人及登記持有人以本身名義申請證券或轉讓或受讓證券時或尋求香港證券登記處的服務時，必須向本公司或其代理及香港證券登記處提供準確個人資料。未能提供所要求的資料可能會導致閣下的證券申請被拒或延遲，或本公司或香港證券登記處無法進行過戶或以其他方式提供服務。此舉亦可能妨礙或延遲登記或轉讓閣下已成功申請的香港發售股份及／或寄發閣下應得的股票及／或退款支票。

證券持有人所提供的個人資料如有任何錯誤，請立即通知本公司及香港證券登記處。

#### 2. 用途

證券持有人的個人資料可作以下用途及以任何方式持有、處理及／或保存：

- 處理閣下的申請及退款支票及電子退款指示(如適用)、核實是否符合申請表格及招股章程載列的條款與申請手續及公佈香港發售股份的分派結果；
- 遵守香港及其他地區的適用法例及法規；
- 以證券持有人(包括香港結算代理人(如適用))的身份登記及發行證券或轉讓或受讓證券；
- 存置或更新本公司的證券持有人名冊；
- 核實證券持有人身份；
- 確定本公司證券持有人的受益權利，例如股息、供股及紅股等；
- 分發本公司及其附屬公司的通訊；
- 編製統計數據及股東資料；
- 披露有關資料以便就權益提出申索；及
- 與上述者有關的任何其他附帶或相關用途及／或讓本公司及香港證券登記處能履行對證

券持有人及／或監管機構承擔的責任及／或證券持有人不時同意的任何其他用途。

#### 3. 轉交個人資料

本公司及香港證券登記處會對持有關證券持有人的個人資料保密，但本公司及香港證券登記處可在作上述任何用途屬必要之情況下，向下列任何人士披露或轉交(不論在香港境內或境外)有關個人資料：

- 本公司委任的代理，例如印刷顧問、收款銀行及海外受件過戶登記總處；
- (如證券持有人要求將證券存於中央結算系統)香港結算或香港結算代理人，彼等將會於中央結算系統的操作使用有關個人資料；
- 向本公司或香港證券登記處提供與其各自業務運作有關的行政、電訊、電腦、付款或其他服務的任何代理、承辦商或第三方服務供應商；
- 交易所、證監會及任何其他法定監管機關或政府部門或法例、規則或法規另行規定者；及
- 證券持有人與之有業務往來或擬有業務往來的任何人士或機構，例如彼等的銀行、律師、會計師或股票經紀等。

#### 4. 保留個人資料

本公司及香港證券登記處將按收集個人資料所需的用途保留證券申請人及持有人的個人資料。無需保留的個人資料將會根據條例銷毀或處理。

#### 5. 查閱及更正個人資料

證券持有人有權確定本公司或香港證券登記處是否持有其個人資料，並有權索取有關資料的副本及更正任何不準確資料。本公司及香港證券登記處有權就處理該等要求收取合理費用。

所有查閱資料或更正資料的要求應按招股章程「公司資料」一節所披露或不時通知的本公司註冊地址送交公司秘書，或向香港證券登記處的私隱事務主任提出。

閣下簽署申請表格或向香港結算發出電子認購指示，即表示同意上述各項。